To establish a reliable relationship with shareholders, employees, and other stakeholders, a robust corporate governance structure is key. In addition, it is also crucial to ensure Moberg Pharma is managed responsibly, and in compliance with applicable laws, regulations, and best practices governing the company's operations.
Following market approval in 13 EU countries and the launch that started spring 2024 in Sweden, Moberg Pharma is now in a transformation phase from a late-stage pharmaceutical development company to launching the competencies needed to be a company with pharmaceuticals on the market. This means among other things more focus on quality systems and sourcing. Corporate governance work creates the conditions for Moberg Pharma to ensure that it meets the expectations it faces, including how sustainability issues are integrated throughout the business.
One focus area in 2025 was to digitalize quality-related and regulatory processes to ensure a more efficient European expansion. We continue to work with continuity risks in the company’s operations, including by securing a long-term supply of terbinafine. The new terbinafine manufacturer that was qualified in 2024 is now being used in series production with good results. In March 2026, an additional terbinafine supplier was approved. Overall, the year produced further improvements in corporate governance that even better prepare Moberg Pharma for the future. Corporate Governance Report 2025